These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 35405011)

  • 21. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies.
    Luo X; Hou L; Liang L; Dong G; Shen S; Zhao Z; Gong CX; Li Y; Du ML; Su Z; Du H; Yan C
    Eur J Endocrinol; 2017 Aug; 177(2):195-205. PubMed ID: 28566441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
    Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
    Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Pediatric Growth Hormone Therapy: Results From the Full KIGS Cohort.
    Maghnie M; Ranke MB; Geffner ME; Vlachopapadopoulou E; Ibáñez L; Carlsson M; Cutfield W; Rooman R; Gomez R; Wajnrajch MP; Linglart A; Stawerska R; Clayton PE; Darendeliler F; Hokken-Koelega ACS; Horikawa R; Tanaka T; Dörr HG; Albertsson-Wikland K; Polak M; Grimberg A
    J Clin Endocrinol Metab; 2022 Nov; 107(12):3287-3301. PubMed ID: 36102184
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: Results from REAL4, a phase 3 clinical trial.
    Mori J; Ohata Y; Fujisawa Y; Sato Y; Röhrich S; Rasmussen MH; Bang RB; Horikawa R
    Clin Endocrinol (Oxf); 2024 Apr; 100(4):389-398. PubMed ID: 38368603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 24-month use of once-weekly GH, LB03002, in prepubertal children with GH deficiency.
    Khadilkar V; Radjuk KA; Bolshova E; Khadgawat R; El Kholy M; Desai M; Peterkova V; Mericq V; Kratzsch J; Siepl EC; Martin D; Lopez P; Ji HJ; Bae YJ; Lee JH; Saenger PH
    J Clin Endocrinol Metab; 2014 Jan; 99(1):126-32. PubMed ID: 24170106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of efficacy and safety of long-acting PEGylated recombinant human growth hormone (Jintrolong) for patients with growth hormone deficiency.
    Du H; Wu D; Yi P; Bai X; Luo Y; Yang H; Chen S; Pan H; Zhu H
    J Pediatr Endocrinol Metab; 2022 Apr; 35(4):511-517. PubMed ID: 35245011
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
    Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
    J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Weekly Somapacitan in GH Deficiency: 4-Year Efficacy, Safety, and Treatment/Disease Burden Results From REAL 3.
    Sävendahl L; Battelino T; Højby Rasmussen M; Brod M; Röhrich S; Saenger P; Horikawa R
    J Clin Endocrinol Metab; 2023 Sep; 108(10):2569-2578. PubMed ID: 36995872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gene Expression Signatures Predict First-Year Response to Somapacitan Treatment in Children With Growth Hormone Deficiency.
    Garner T; Clayton P; Højby M; Murray P; Stevens A
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1214-1221. PubMed ID: 38066644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis.
    Zhu J; Yuan K; Rana S; Jakki SL; Bhat AS; Liang L; Wang C
    Sci Rep; 2024 Apr; 14(1):8061. PubMed ID: 38580693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
    Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
    Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Daily Growth Hormone Injection Adherence and Height Among Children With Growth Hormone Deficiency.
    Loftus J; Miller BS; Parzynski CS; Alvir J; Chen Y; Jhingran P; Gupta A; DeKoven M; Divino V; Tse J; He J; Wajnrajch M
    Endocr Pract; 2022 Jun; 28(6):565-571. PubMed ID: 35263660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and Efficacy of Lonapegsomatropin in Children With Growth Hormone Deficiency: enliGHten Trial 2-Year Results.
    Maniatis AK; Casella SJ; Nadgir UM; Hofman PL; Saenger P; Chertock ED; Aghajanova EM; Korpal-Szczyrska M; Vlachopapadopoulou E; Malievskiy O; Chaychenko T; Cappa M; Song W; Mao M; Mygind PH; Smith AR; Chessler SD; Komirenko AS; Beckert M; Shu AD; Thornton PS
    J Clin Endocrinol Metab; 2022 Jun; 107(7):e2680-e2689. PubMed ID: 35428884
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biosynthetic human growth hormone in the treatment of growth hormone deficiency.
    Holcombe JH; Conforti PM; Wong AC; Thompson RG; Draper MW
    Acta Paediatr Scand Suppl; 1990; 367():44-8. PubMed ID: 2220388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope
    Backeljauw P; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
    J Pediatr Endocrinol Metab; 2021 Apr; 34(4):431-440. PubMed ID: 33647196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and Overall Safety of NutropinAq
    Coutant R; Bosch Muñoz J; Dumitrescu CP; Schnabel D; Sert C; Perrot V; Dattani M
    Front Endocrinol (Lausanne); 2021; 12():676083. PubMed ID: 34113318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of the efficacy and safety of recombinant human growth hormone in treating idiopathic short stature and growth hormone deficiency in children.
    Hou L; Liang Y; Wu W; Lin HH; Luo XP; Ying YQ
    Growth Horm IGF Res; 2020; 53-54():101331. PubMed ID: 32777706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: A systematic review and meta-analysis.
    Mameli C; Orso M; Calcaterra V; Wasniewska MG; Aversa T; Granato S; Bruschini P; Guadagni L; d'Angela D; Spandonaro F; Polistena B; Zuccotti G
    Pharmacol Res; 2023 Jul; 193():106805. PubMed ID: 37236413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and effectiveness of Omnitrope
    Backeljauw P; Kanumakala S; Loche S; Schwab KO; Miller BS; Levy R; McCormick K; Zouater H; Zabransky M; Campbell K
    Eur J Pediatr; 2022 Jun; 181(6):2367-2378. PubMed ID: 35275291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of LB03002, a once-weekly sustained-release human GH for 12-month treatment in Korean children with GH deficiency.
    Hwang JS; Lee HS; Chung WY; Han HS; Jin DK; Kim HS; Ko CW; Lee BC; Lee DY; Lee KH; Shin JH; Suh BK; Yoo HW; Ji HJ; Lee JH; Bae YJ; Kim DH; Yang SW
    Eur J Endocrinol; 2013 Aug; 169(2):179-85. PubMed ID: 23682096
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.